Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2016

Tofacitinib has been released from the FDA’s risk evaluation and mitigation strategy requirement. The FDA is also reviewing a biologics license application for ABP-501, an adalimumab biosimilar. And CHS-0214, a proposed etanercept biosimilar, has met its primary endpoint at Week 24 in an ongoing 52-week study…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabetanerceptFDAFood and Drug AdministrationTofacitinib

The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

Susan Bernstein  |  March 1, 2016

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

Filed under:Biologics/DMARDsDrug Updates Tagged with:American College of Rheumatology (ACR)BiosimilarscostsFDAFood and Drug Administrationinfliximab

Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis

Lara C. Pullen, PhD  |  February 29, 2016

Secukinumab, an anti-interleukin-17A monoclonal antibody, has successfully completed multiple clinical trials, which found the intravenous treatment may be safe and effective for treating patients with active ankylosing spondylitis…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisAnti-TNFanti-tumor necrosis factorsecukinumab

The Effect of Tofacitinib on Live Vaccine Responses

Richard Quinn  |  February 26, 2016

New research indicates that vaccination for the herpes zoster virus in patients with rheumatoid arthritis starting tofacitinib appears to be both safe and useful. Rheumatologists may want to check the patient’s pre-existing immunity status prior to administering the vaccine…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis

Dermatology & Immunology: Skin Issues Can Present Challenges

Thomas R. Collins  |  February 23, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

Filed under:ConditionsMyositisSystemic Lupus Erythematosus Tagged with:2015 ACR/ARHP Annual MeetingDermatologydermatomyositisImmunologyLupusskin

What Listening to Lungs Might Teach About Rheumatic Disease

Simon M. Helfgott, MD  |  February 17, 2016

One of your first clinical assignments as a medical student was likely to have been the lung exam. Its key descriptors may still resonate in your mind: inspection, palpation, percussion and auscul­tation. Proudly parading down the hospital corridors, your newly purchased stethoscope snugly tucked inside your lab coat pocket, you carefully place its cold metal…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:examlungspatient carePulmonaryRheumatic Diseaserheumatologist

Case Study in Dermatology: Tender Papules on Elbows, Hands in RA

Drew Kurtzman, MD, & Timothy McCalmont, MD, with Ruth Ann Vleugels, MD, MPH, & Joseph F. Merola, MD, MMSc  |  February 17, 2016

The Case A 41-year-old woman was referred to the dermatology clinic for a three-month history of tender lesions on her elbows and around the joints of her hands. Her medical history was notable for seropositive, non-erosive rheumatoid arthritis (RA), which was being treated with 5 mg pred­nisone daily, 10 mg methotrexate weekly by mouth, 200…

Filed under:ConditionsRheumatoid Arthritis Tagged with:case reportClinicalDermatologyDiagnosispapulespatient careRheumatoid arthritisrheumatologyTreatment

Tofacitinib Decreases Inflammation in Early RA

Michele B. Kaufman, PharmD, BCGP  |  February 12, 2016

A recent study used MRI to show that tofacitinib reduces inflammation and inhibition of the progression of structural damage in adults with early RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Magnetic resonance imaging (MRI)MethotrexateMRIRheumatoid Arthritis (RA)Tofacitinib

Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 3, 2016

An etanercept biosimilar referencing Enbrel and designed to treat multiple autoimmune diseases has been approved for the European market. Also, an application for subcutaneous brodalumab to treat plaque psoriasis has been submitted to the FDA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsbrodalumabetanerceptEuropean UnionFDAFood and Drug Administration

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

Michele B. Kaufman, PharmD, BCGP  |  January 27, 2016

Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:combination therapyDisease-modifying antirheumatic drugs (DMARDs)Psoriatic ArthritisRheumatoid Arthritis (RA)sirukumabTNF inbhibitor

  • « Previous Page
  • 1
  • …
  • 69
  • 70
  • 71
  • 72
  • 73
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences